Supplemental Figures S1-S42 from The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets
Year: 2026
Type: supplementary-materials
Abstract: Supplemental Figure 1: Modeled CN vs. AmpRatio Supplemental Figure 2: Amplification ratio purity invariance Supplemental Figure 3: Modeled gene CN vs. AmpRatio Supplemental Figure 4: CONSORT diagram Supplemental Figure 5: Pan-tumor MDM2 amplification landscape Supplemental Figure 6: MDM2 co-alteration landscape Supplemental Figure 7: Tissue ploidy distribution by tumor type Supplemental Figure 8: CN segment length vs. AmpRatio Supplemental Figure 9: Amplicon focality Supplemental Figure 10: Pan-tumor AmpRatio distribution of emerging targets Supplemental Figure 11: Breast ERBB2 co-alteration landscape Supplemental Figure 12: GE ERBB2 co-alteration landscape Supplemental Figure 13: CRC ERBB2 co-alteration landscape Supplemental Figure 14: Breast CGDB CONSORT diagram Supplemental Figure 15: GE CGDB CONSORT diagram Supplemental Figure 16: CRC CGDB CONSORT diagram Supplemental Figure 17: rwPFS for ERBB2-amplified mBC, aGE, and mCRC patients treated with trastuzumab-based regimens Supplemental Figure 18: Exploratory AmpRatio cutoffs for ERBB2-amplified mBC, aGE, and mCRC patients treated with trastuzumab-based regimens Supplemental Figure 19: Outcomes for ERBB2-amplified mBC patients treated with T-DXd Supplemental Figure 20: Exploratory AmpRatio cutoffs for ERBB2-amplified mBC patients treated with T-DXd Supplemental Figure 21: Performance of ERBB2 AmpRatio for predicting HER2-positivity Supplemental Figure 22: Association between ERBB2 AmpRatio and HER2 IHC/FISH Supplemental Figure 23: rwPFS on anti-HER2 regimens within HER2 IHC-defined subgroups Supplemental Figure 24: Exploratory AmpRatio cutoffs for anti-HER2 regimens within HER2 IHC-defined subgroups Supplemental Figure 25: Outcomes for HER2+ mBC patients treated with T-DXd Supplemental Figure 26: Exploratory AmpRatio cutoffs for HER2+ mBC patients treated with T-DXd Supplemental Figure 27: Outcomes for HER2+ mBC patients treated with T-DM1 Supplemental Figure 28: Exploratory AmpRatio cutoffs for HER2+ mBC patients treated with T-DM1 Supplemental Figure 29: Sensitivity analysis for outcomes of HER2+ mBC treated with 1L trastuzumab-based regimens Supplemental Figure 30: Sensitivity analysis for outcomes of HER2+ mBC treated with T-DXd Supplemental Figure 31: Sensitivity analysis for outcomes of HER2+ mBC treated with T-DM1 Supplemental Figure 32: Outcomes for HER2+ aGE patients treated with 1L trastuzumab-based regimens Supplemental Figure 33: Sensitivity analysis for outcomes of HER2+ aGE treated with 1L trastuzumab-based regimens Supplemental Figure 34: NSCLC MET co-alteration landscape Supplemental Figure 35: NSCLC EGFR co-alteration landscape Supplemental Figure 36: Ovarian CCNE1 amplification landscape Supplemental Figure 37: Serous Ovarian CCNE1 co-alteration landscape Supplemental Figure 38: ctDNA TF distribution by alteration type Supplemental Figure 39: ctDNA TF distribution by tumor type Supplemental Figure 40: All-gene liquid amplification concordance Supplemental Figure 41: Tissue and Liquid AmpRatio Correlation Supplemental Figure 42: Distribution of ctDNA TF and AmpRatio for discordant vs. concordant liquid samples.
Authors: Jessica K. Lee, Julia C.F. Quintanilha, Kuei-Ting Chen, Bernard Fendler, Candice Francheska B. Tambaoan, Ryon Graf, Nicole Odzer, Lajos Pusztai, Maryam Lustberg, Harshabad Singh, Matthew Strickland, Tess A. O’Meara, Sara M. Tolaney, Timothy A. Yap, Jeffrey Ross, Amaya Gasco Hernandez, Brennan Decker, Richard S.P. Huang, Samuel J. Klempner, Ethan S. Sokol, Alexa B. Schrock
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7166797372
Cites:
Cited by:
Related to: